Shaping the future of gastrointestinal cancers through metabolic interactions with host gut microbiota
Wen Xie,
Aditi Sharma,
Hitesh Kaushik,
Lalit Sharma,
Nistha,
Md Khalid Anwer,
Monika Sachdeva,
Gehan M. Elossaily,
Yingbo Zhang,
Ramkumar Pillappan,
Maninderjit Kaur,
Tapan Behl,
Bairong Shen,
Rajeev K. Singla
Affiliations
Wen Xie
Department of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China
Aditi Sharma
School of Pharmaceutical Sciences, Shoolini University, Solan, H.P, 173229, India
Hitesh Kaushik
School of Pharmaceutical Sciences, Shoolini University, Solan, H.P, 173229, India
Lalit Sharma
School of Pharmaceutical Sciences, Shoolini University, Solan, H.P, 173229, India
Nistha
School of Pharmaceutical Sciences, Shoolini University, Solan, H.P, 173229, India
Md Khalid Anwer
Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia
Monika Sachdeva
Fatima College of Health Sciences, Al Ain, United Arab Emirates
Gehan M. Elossaily
Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, P.O. Box 71666, Riyadh, 11597, Saudi Arabia
Yingbo Zhang
Department of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China; School of Pharmaceutical Sciences, Shoolini University, Solan, H.P, 173229, India; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia; Fatima College of Health Sciences, Al Ain, United Arab Emirates; Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, P.O. Box 71666, Riyadh, 11597, Saudi Arabia; Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences, Mangaluru, Karnataka, India; Department of Pharmaceutical Sciences, lovely Professional University, Phagwara, India; Amity School of Pharmaceutical Sciences, Amity University, Sahibzada Ajit Singh Nagar, Punjab, India; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 1444411, India; Institutes for Systems Genetics, West China Tianfu Hospital, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610218, China
Ramkumar Pillappan
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences, Mangaluru, Karnataka, India
Maninderjit Kaur
Department of Pharmaceutical Sciences, lovely Professional University, Phagwara, India
Tapan Behl
Amity School of Pharmaceutical Sciences, Amity University, Sahibzada Ajit Singh Nagar, Punjab, India; Corresponding author.
Bairong Shen
Department of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China; Corresponding author.
Rajeev K. Singla
Department of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 1444411, India; Corresponding author. Department of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Gastrointestinal (GI) cancers represent a significant global health challenge, driving relentless efforts to identify innovative diagnostic and therapeutic approaches. Recent strides in microbiome research have unveiled a previously underestimated dimension of cancer progression that revolves around the intricate metabolic interplay between GI cancers and the host's gut microbiota. This review aims to provide a comprehensive overview of these emerging metabolic interactions and their potential to catalyze a paradigm shift in precision diagnosis and therapeutic breakthroughs in GI cancers. The article underscores the groundbreaking impact of microbiome research on oncology by delving into the symbiotic connection between host metabolism and the gut microbiota. It offers valuable insights into tailoring treatment strategies to individual patients, thus moving beyond the traditional one-size-fits-all approach. This review also sheds light on novel diagnostic methodologies that could transform the early detection of GI cancers, potentially leading to more favorable patient outcomes. In conclusion, exploring the metabolic interactions between host gut microbiota and GI cancers showcases a promising frontier in the ongoing battle against these formidable diseases. By comprehending and harnessing the microbiome's influence, the future of precision diagnosis and therapeutic innovation for GI cancers appears more optimistic, opening doors to tailored treatments and enhanced diagnostic precision.
